Food and Drug Administration Monday approved Merck 'Woven designed to protect infants from syncytial respiratory virus during their first season of the virus, bringing a rival to similar treatment on the market from a similar treatment from Sanofi And Astrazeneca.
The decision will allow the company to launch the medication, which will be marketed as a thick, before the RSV season which generally starts towards fall and winter and lasts in spring. Merck said in a press release that he expects to expect the orders to start the shot in July, the shipments delivered before the virus will start to spread widely.
Approval gives doctors a new processing option for the virus, making thousands of older Americans and hundreds of deaths among infants each year. RSV complications are the main cause of hospitalization among newborns.
“We are committed to ensuring the availability of [Enflonsia] In the United States, before the start of the next RSV season to help reduce the important burden of this generalized seasonal infection on families and health care systems, “said Dr. Dean Li, president of Merck Research Laboratories, in a statement.
Merck's shooting will compete against a similar success treatment by Sanofi and Astrazeneca called Beyfortus, which was in a shortage nationally during the 2023 RSV season due to unprecedented demand.
Both are preventive monoclonal antibodies, which provide antibodies directly in the blood circulation to provide immediate protection. But everyone targets a different part of the virus, which makes it difficult to compare them directly.
Merck's treatment can be administered to infants whatever their weight, which, depending on the company, can offer a convenience in terms of dosage. Meanwhile, Beyfortus' recommended dose is based on the body weight of an infant.
Sanofi revealed on Monday an aggressive effort to increase the offer of Beyfortus, including a plan to start sending the shot at the beginning of the third quarter. Last year, Beyfortus reserved sales of 1.7 billion euros ($ 1.8 billion).
RSV vaccines are also available in the United States from companies such as Pfizer,, GSK And Modern. But these blows are only used in adults or pregnant women. Recently, the FDA has interrupted RSV fire tests in young children while it evaluates security problems.
All market companies await a meeting of external vaccine advisers to centers for Disease Control and Prevention from June 25 to 27, when they form recommendations for RSV shooting and other vaccinations.
In the midst of the middle at the end of the influenza, the treatment reduced RSV hospitalizations by more than 84% and reduced hospitalizations due to 90% of lower respiratory infections compared to a placebo in infants for five months. The shooting has also reduced lower respiratory infections which required medical care by more than 60% compared to a placebo at five months.
RSV is a frequent cause of lower respiratory tract infections such as pneumonia.